Navigation Links
Technology Developments Drive Growth in the Global Enzyme-Linked Immunosorbent Assay (ELISA) Market, According to New Report by Global Industry Analysts, Inc.
Date:9/25/2013

San Jose, California (PRWEB) September 25, 2013

Follow us on LinkedIn – Enzyme-Linked Immunosorbent Assay (ELISA) is one of the few assay formats to find widespread popularity in a rapidly changing life sciences and drug discovery market. However, over the last few years, the market has been witnessing negative growth due to the adoption of new technologies by researchers, particularly multiplex proteomic array platforms. The growing preference for multiplex proteomic arrays has been cannibalizing the popularity of ELISA. Growth in the market is thereby being restricted only to laboratories seeking cost-effective technology options. In addition to the competitive threat posed by multiplex assays, manufacturers have been facing a major challenge in the form of increasing commoditization of ELISA products. Commoditization of ELISA products has intensified pricing pressures for manufacturers. To counter the challenges, manufacturers are targeting niche markets and are focusing on the development of innovative products.

Although the new multiplex proteomic array technology has dented sales of ELISA products, demand will continue to hold ground in the short to medium term owing in part to its use as a secondary validation process by multiplex customers. This is largely due to the quality and established credential of Research ELISA products. Cost-effective Research ELISA products are preferred by laboratories and researchers dealing with less number of analytes and high sensitivity of assays. Another factor enabling ELISA’s sustenance in the immunoassay market is the development of automated platforms. These platforms, specifically designed for running ELISA, offer improved performance, increased productivity, greater sensitivity, better uniformity, improved speed, reduced assay time, cycle time, higher throughput, miniaturization, elimination of time consuming wash steps, and the flexibility to adapt a range of assays/protocol. In addition, the relatively low penetration of fully automated ELISA offers a solid business case for cellular ELISA manufacturers to tap into the large untapped potential.

As stated by the new market research report on Enzyme-Linked Immunosorbent Assay (ELISA), the United States represents the largest market for Research ELISA worldwide. ELISA Kits represents the largest market segment. However, tough competition from proteomic technology is expected to result in significant erosion of revenues in the segment in the coming years. The market for ELISA Development Sets and Antibody Pairs is also expected to witness significant downward pressure over the analysis period. However, the slump in the segment is expected to be relatively smaller as compared to ELISA Kits, as end-users in this market largely comprise of price sensitive laboratories, which exhibit reluctance in adopting expensive multiplex proteomic array technologies.

Major players covered in the report include American Laboratory Products Company (ALPCO), BD Biosciences, BioMérieux SA, Bio-Rad Laboratories Inc., EMD Millipore Corp., Life Technologies Corporation, Ortho-Clinical Diagnostics Inc., R&D Systems Inc., Thermo Fisher Scientific Inc., and ZEUS Scientific Inc.

The research report titled “Enzyme-Linked Immunosorbent Assay (ELISA): A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities. The report provides market estimates and projections for Research Enzyme-Linked Immunosorbent Assay (ELISA) in value (US$) for all major geographic markets such as the US, Canada, Japan, Europe (France, Germany, Italy, UK and Rest of Europe), Asia-Pacific, Latin America, and Rest of World.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Enzyme_Linked_Immunosorbent_Assay_ELISA_Market_Report.asp.

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###

Read the full story at http://www.prweb.com/releases/ELISA_kits_market/immunology_research/prweb11160550.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Convoy Therapeutics Granted Patent for Proprietary SPACE Technology
2. SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
3. Xinmeiya Technology Releases Their 5C7-195 Benchtop Thermoelectric Controller
4. Global Chiral Technology Market 2013 - 2017
5. Industry Shares, Size, Trend, Analysis, and Forecasts to 2017: ResearchMoz.us
6. Industry Leaders Drive SPIE Photomask Technology Conference
7. Autonomous Vehicle Technology Could Help Blind to Navigate
8. Evonik and Genedata Broaden Their Collaboration with the Genedata Selector Biotechnology Data Management Platform
9. Nanoly Bioscience to Develop CU-Boulder Vaccine Stabilization Technology
10. BCC Research Publishes a New Report on U.S. Markets for Environmental Biotechnology Products
11. Genia Technologies, Columbia University, and Harvard University Awarded $5.25 Million Grant from NIH to Accelerate the Development of NanoTag DNA Sequencing Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ACEA Biosciences, ... its Phase I/II clinical trials for AC0010 at the World Conference on Lung Cancer ... providing an update on the phase I/II clinical trials for AC0010 in patients with ...
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only way to ... technology experience. All three tenets were on display at the 2nd Annual DrugDev User ... 40 sponsor, CRO and site organizations to discuss innovation and the future of clinical ...
(Date:12/2/2016)... , December 2, 2016 The ... 2021, growing at a CAGR of 7.3% during the forecast period ... hospitals and diagnostic laboratories segment accounted for the largest share of ... ... report on global immunohistochemistry (IHC) market spread across 225 pages, profiling ...
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is excited to announce the formation of ... developing preclinical ophthalmology assets through proof of concept. ... created by Portage Pharmaceuticals Limited and being developed ... surface and anterior segment diseases. This agent has ...
Breaking Biology Technology:
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
(Date:11/29/2016)... -- BioDirection, a privately held medical device company developing ... of concussion and other traumatic brain injury (TBI), announced ... with the U.S. Food and Drug Administration (FDA) to ... the meeting company representatives reviewed plans for clinical development ... of a planned pilot trial. "We ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
Breaking Biology News(10 mins):